PhIII details boost Acorda as execs rush to FDA with the clock ticking on a time bomb
Shares of Acorda got a boost after the market closed on Monday as investors got a chance to look over the detailed Phase III data for its inhaled levodopa drug CVT-301. And while we already knew that the top-line data on the primary endpoint for Parkinson’s disease were positive, it seemed to help that this late-stage therapy appears on track to arrive at the FDA later this month as company execs look to replace its big moneymaker, now poised to lose patent protection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
